Literature DB >> 22806318

The predictive value of chronic kidney disease for assessing cardiovascular events under consideration of pretest probability for coronary artery disease in patients who underwent stress myocardial perfusion imaging.

Tatsuhiko Furuhashi1, Masao Moroi, Nobuhiko Joki, Hiroki Hase, Hirofumi Masai, Taeko Kunimasa, Hiroshi Fukuda, Kaoru Sugi.   

Abstract

Pretest probability of coronary artery disease (CAD) facilitates diagnosis and risk stratification of CAD. Stress myocardial perfusion imaging (MPI) and chronic kidney disease (CKD) are established major predictors of cardiovascular events. However, the role of CKD to assess pretest probability of CAD has been unclear. This study evaluates the role of CKD to assess the predictive value of cardiovascular events under consideration of pretest probability in patients who underwent stress MPI. Patients with no history of CAD underwent stress MPI (n = 310; male = 166; age = 70; CKD = 111; low/intermediate/high pretest probability = 17/194/99) and were followed for 24 months. Cardiovascular events included cardiac death and nonfatal acute coronary syndrome. Cardiovascular events occurred in 15 of the 310 patients (4.8 %), but not in those with low pretest probability which included 2 CKD patients. In patients with intermediate to high pretest probability (n = 293), multivariate Cox regression analysis identified only CKD [hazard ratio (HR) = 4.88; P = 0.022) and summed stress score of stress MPI (HR = 1.50; P < 0.001) as independent and significant predictors of cardiovascular events. Cardiovascular events were not observed in patients with low pretest probability. In patients with intermediate to high pretest probability, CKD and stress MPI are independent predictors of cardiovascular events considering the pretest probability of CAD in patients with no history of CAD. In assessing pretest probability of CAD, CKD might be an important factor for assessing future cardiovascular prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806318     DOI: 10.1007/s10554-012-0097-2

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  26 in total

1.  Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group.

Authors:  A B Newman; L Shemanski; T A Manolio; M Cushman; M Mittelmark; J F Polak; N R Powe; D Siscovick
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 3.  ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing).

Authors:  R J Gibbons; G J Balady; J W Beasley; J T Bricker; W F Duvernoy; V F Froelicher; D B Mark; T H Marwick; B D McCallister; P D Thompson; W L Winters; F G Yanowitz; J L Ritchie; R J Gibbons; M D Cheitlin; K A Eagle; T J Gardner; A Garson; R P Lewis; R A O'Rourke; T J Ryan
Journal:  J Am Coll Cardiol       Date:  1997-07       Impact factor: 24.094

4.  Impact of chronic kidney disease and stress myocardial perfusion imaging as a predictor of cardiovascular events.

Authors:  Tatsuhiko Furuhashi; Masao Moroi; Nobuhiko Joki; Hiroki Hase; Hirofumi Masai; Taeko Kunimasa; Ryo Nakazato; Hiroshi Fukuda; Kaoru Sugi
Journal:  Ann Nucl Med       Date:  2011-07-01       Impact factor: 2.668

5.  A clinically relevant classification of chest discomfort.

Authors:  G A Diamond
Journal:  J Am Coll Cardiol       Date:  1983-02       Impact factor: 24.094

6.  Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction.

Authors:  R Hachamovitch; D S Berman; L J Shaw; H Kiat; I Cohen; J A Cabico; J Friedman; G A Diamond
Journal:  Circulation       Date:  1998-02-17       Impact factor: 29.690

7.  Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography.

Authors:  D S Berman; R Hachamovitch; H Kiat; I Cohen; J A Cabico; F P Wang; J D Friedman; G Germano; K Van Train; G A Diamond
Journal:  J Am Coll Cardiol       Date:  1995-09       Impact factor: 24.094

8.  Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease.

Authors:  A R Galassi; S Azzarelli; A Tomaselli; R Giosofatto; A Ragusa; S Musumeci; C Tamburino; G Giuffrida
Journal:  Am J Cardiol       Date:  2001-07-15       Impact factor: 2.778

9.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.

Authors:  Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

10.  Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study.

Authors:  D S Berman; H Kiat; J D Friedman; F P Wang; K van Train; L Matzer; J Maddahi; G Germano
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

View more
  1 in total

1.  Impact of renal dysfunction on the choice of diagnostic imaging, treatment strategy, and outcomes in patients with stable angina.

Authors:  Takao Kato; Yukari Uemura; Masanao Naya; Mitsuru Momose; Naoya Matsumoto; Eriko Suzuki; Satoshi Hida; Takatomo Nakajima; Takao Yamauchi; Nagara Tamaki
Journal:  Sci Rep       Date:  2019-05-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.